旗下尤靖安被列入疫情防治緊急戰略物資之一 李氏大藥廠(00950.HK)股價高開1.6倍後升幅大縮至僅三成
李氏大藥廠(00950.HK)公布,旗下自研產品抗病毒藥物「尤靖安」被列入今次武漢新型冠狀病毒性肺炎疫情防治的緊急戰略物資之一。該股今早大裂口高開近1.6倍報11元創逾年半高欠承接,曾回順至5.36元,現造5.52元,漲30%,一向稀疏成交激增至2,214萬股,為近三年罕見,涉資1.32億元。
李氏公布,旗下抗病毒藥物「尤靖安」被安徽省經濟和信息化廳列入「安徽省應急藥品生產企業目錄」和「國家工業和信息化部重點物資保障信息監控平台」,成為今次疫情防治的緊急戰略物資之一。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.